MET overexpression in ovarian cancer via CD24‐induced downregulation of miR‐181a: A signalling for cellular quiescence‐like state and chemoresistance in ovarian CSCs

Abstract

AbstractIncreased expression of CD24 and MET, markers for cancer stem‐like cells (CSCs), are each associated with ovarian cancer severity. However, whether CD24 and MET are co‐expressed in ovarian CSCs and, if so, how they are related to CSC phenotype manifestation remains unknown. Our immunohistochemistry analysis showed that the co‐expression of CD24 and MET was associated with poorer patient survival in ovarian cancer than those without. In addition, analyses using KM plotter and ROC plotter presented that the overexpression of CD24 or MET in ovarian cancer patients was associated with resistance to platinum‐based chemotherapy. In our miRNA transcriptome and putative target genes analyses, miR‐181a was downregulated in CD24‐high ovarian cancer cells compared to CD24‐low and predicted to bind to CD24 and MET 3'UTRs. In OV90 and SK‐OV‐3 cells, CD24 downregulated miR‐181a expression by Src‐mediated YY1 activation, leading to increased expression of MET. And, CD24 or MET knockdown or miR‐181a overexpression inhibited the manifestation of CSC phenotypes, cellular quiescence‐like state and chemoresistance, in OV90 and SK‐OV‐3 cells: increased colony formation, decreased G0/G1 phase cell population and increased sensitivity to Cisplatin and Carboplatin. Our findings suggest that CD24‐miR‐181a‐MET may consist of a signalling route for ovarian CSCs, therefore being a combinatory set of markers and therapeutic targets for ovarian CSCs.